Are we still scratching the surface? A case of intractable pruritus following systemic opioid analgesia

Journal of Opioid Management

Volumn 3, Issue 3, 2007, Pages 167-170

  Tarcatu, Dana ^a   Tamasdan, Cristina ^a   Moryl, Natalie ^a   Obbens, Eugenie ^a  

^a MEMORIAL SLOAN KETTERING CANCER CENTER   (United States)

Author keywords

Opioid rotation; Pruritus; Systemic opioids

Indexed keywords

ANTIHISTAMINIC AGENT; DIPHENHYDRAMINE; FENTANYL; HYDROMORPHONE; HYDROXYZINE; MORPHINE; MORPHINE SULFATE; NALOXONE; NARCOTIC ANALGESIC AGENT; OXYCODONE; VINCRISTINE;

ACUTE GRANULOCYTIC LEUKEMIA; ADOLESCENT; ANALGESIA; ARTICLE; CANCER CHEMOTHERAPY; CANCER RADIOTHERAPY; CASE REPORT; CONTINUOUS INFUSION; DISEASE SEVERITY; DRUG DOSE TITRATION; DRUG SUBSTITUTION; DRUG WITHDRAWAL; FEBRILE NEUTROPENIA; HOSPITAL ADMISSION; HUMAN; MALE; MUCOSA INFLAMMATION; NAUSEA; PAIN; PELVIS TUMOR; PRURITUS; SYMPTOM; VOMITING;

EID: 34547849458     PISSN: 15517489     EISSN: None     Source Type: Journal    
DOI: 10.5055/jom.2007.0055     Document Type: Article

References (28)

1. Ballantyne JC, Loach AB, Carr DB: The incidence of pruritus after epidural morphine. Anaesthesia. 1989; 44(10): 863.
2. Woodham M: Pruritus with sublingual buprenorphine. Anaesthesia. 1988; 43(9): 806-807.
3. Katcher J, Walsh D: Opioid-induced itching: Morphine sulfate and hydromorphone hydrochloride. J Pain Symptom Manage. 1999; 17(1): 70-72.
4. Ballantyne JC, Loach AB, Can DB: Itching after epidural and spinal opiates. Pain. 1988; 33(2): 149-160.
5. Andrew D, Schmelz M, Ballantyne JC: Itch - mechanisms and mediators. In Dostrovsky JO, Carr DB, Koltzenburg M (eds.): Proceedings of the 10th World Congress on Pain: Progress in Pain Research and Management. Seattle: IASP Press, 2003, pp. 213-226.
6. Atanassoff PG, Brull SJ, Zhang J, et al.: Enhancement of experimental pruritus and mechanically evoked dysesthesiae with local anesthesia. Somatosens Mot Res. 1999; 16(4): 291-298.
7. Ko MC, Song MS, Edwards T, et al.: The role of central μ opioid receptors in opioid-induced itch in primates. J Pharmacol Exp Ther. 2004; 310(1): 169-176.
8. Schmidt R, Schmelz M, Forster C, et al.: Novel classes of responsive and unresponsive C nociceptors in human skin. J Neurosci. 1995; 15(1 Pt 1): 333-341.
9. Weidner C, Klede M, Rukwied R, et al.: Acute effects of substance P and calcitonin gene-related peptide in human skin - a microdialysis study. J Invest Dermatol. 2000; 115(6): 1015-1020.
10. Heyer G, Dotzer M, Diepgen TL, et al.: Opiate and H1 antagonist effects on histamine induced pruritus and alloknesis. Pain. 1997; 73(2): 239-243.
11. Satoh M, Minami M: Molecular pharmacology of the opioid receptors. Pharmacol Ther. 1995; 68(3): 343-364.
12. Fine PG, Portenoy RK: A Clinical Guide to Opioid Analgesia. New York: McGraw-Hill, 2004.
13. Dunteman E, Karanicolas M: Transnasal butorphanol for the treatment of opioid-induced pruritus unresponsive to antihistamines. J Pain Symptom Manage. 1996; 12(4): 255-260.
14. Twycross R, Greaves MW, Handwerker H, et al.: Itch: Scratching more than the surface. QJM 2003; 96(1): 7-26.
15. McQuay H: Opioids in pain management. Lancet. 1999; 353(9171): 2229-2232.
16. Poyhia R, Kalso EA: Antinociceptive effects and central nervous system depression caused by oxycodone and morphine in rats. Pharmacol Toxicol. 1992; 70(2): 125-130.
17. Wang SC: Emetic and antiemetic drugs. In Roots W, Hoffmann F (eds.): Physiological Pharmacology. New York: Academic Press, 1965, pp. 255-328.
18. Ko MC, Lee H, Song MS, et al.: Activation of kappa-opioid receptors inhibits pruritus evoked by subcutaneous or intrathecal administration of morphine in monkeys. J Pharmacol Exp Ther. 2003; 305(1): 173-179.
19. Kumagai H, Utsumi J: Endogenous opioid system in uraemic patients. Br J Clin Pharmacol. Abstracts of the Joint Meeting of the Seventh World Conference on Clinical Pharmacology and Therapeutics IUPHAR - Division of Clinical Pharmacology and the Fourth Congress of the European Association for Pharmacology and Therapeutics. 2000; 282.
20. Okano K, Togashi Y: Anti-pruritic effect of opioid kappa receptor agonist TRK-820. Br J Clin Pharmacol. Abstracts of the Joint Meeting of the Seventh World Conference on Clinical Pharmacology and Therapeutics IUPHAR - Division of Clinical Pharmacology and the Fourth Congress of the European Association for Pharmacology and Therapeutics. 2000; 283.
21. Lugo RA, Kern SE: The pharmacokinetics of oxycodone. J Pain Palliat Care Pharmacother. 2004; 18(4): 17-30.
22. Poyhia R, Vainio A, Kalso E: A review of oxycodone's clinical pharmacokinetics and pharmacodynamics. J Pain Symptom Manage. 1993; 8: 63-67.
23. Lalovic B, Kharasch E, Hoffer C, et al.: Pharmacokinetics and pharmacodynamics of oral oxycodone in healthy human subjects: Role of circulating active metabolites. Clin Pharmacol Ther. 2006; 79(5): 461-479.
24. Mercadante S: Opioid rotation for cancer pain: Rationale and clinical aspects. Cancer. 1999; 86(9): 1856-1866.
25. Gaveriaux-Ruff C, Kieffer BL: Opioid receptors: Gene structure and function. In Stein C (ed.): Opioids in Pain Control: Basic and Clinical Aspects. Cambridge, England: Cambridge University Press, 1999, pp. 1-20.
26. Knapp RJ, Porreca F, Burks TF, et al.: Mediation of analgesia by multiple opioid receptors. In Hill CS, Fields WS (eds.): Advances in Pain Research and Therapy. New York: Raven Press, 1989, pp. 247-289.
27. Kalso F, Vainio A: Morphine and oxycodone hydrochloride in the management of cancer pain. Clin Pharmacol Ther. 1990; 47(5): 639-646.
28. Ikoma A, Steinhoff M, Stander S, et al.: The neurobiology of itch. Nat Rev Neurosci. 2006; 7(7): 535-547.